Copyright
©The Author(s) 2021.
World J Diabetes. Jan 15, 2021; 12(1): 84-97
Published online Jan 15, 2021. doi: 10.4239/wjd.v12.i1.84
Published online Jan 15, 2021. doi: 10.4239/wjd.v12.i1.84
Table 5 Meta-regression analyses of association between weight change difference and difference of alanine aminotransferase, aspartate aminotransferase, magnetic resonance imaging proton density fat fraction, and visceral fat area between antidiabetes drugs and controls (ß coefficient value, P value, and 95%CI are shown)
ß | P value | 95%CI | |
ALT | 0.064 | 0.267 | -0.053-0.181 |
AST | 0.020 | 0.735 | -0.104-0.144 |
MRI-PDFF | 0.308 | 0.701 | -2.678-3.294 |
VFA | 1.776 | 0.343 | -11.723-15.275 |
- Citation: Fu ZD, Cai XL, Yang WJ, Zhao MM, Li R, Li YF. Novel glucose-lowering drugs for non-alcoholic fatty liver disease. World J Diabetes 2021; 12(1): 84-97
- URL: https://www.wjgnet.com/1948-9358/full/v12/i1/84.htm
- DOI: https://dx.doi.org/10.4239/wjd.v12.i1.84